Abstract / Summary
Urinary albumin-to-creatinine ratio (uACR) is a recognized cardiovascular risk marker, but its dynamic changes in heart failure with preserved ejection fraction (HFpEF) remain underexplored. We aimed to identify distinct uACR trajectory patterns and their associations with clinical outcomes in HFpEF patients. We analyzed 746 HFpEF patients with ≥ 3 uACR measurements from the TOPCAT trial. Latent Class Trajectory Modeling identified uACR patterns. The primary outcome was cardiovascular death, aborted cardiac arrest, or heart failure hospitalization. Cox proportional hazards models assessed associations between trajectories and outcomes. Three uACR trajectory patterns emerged: stable (70.5%), decreasing (16.5%), and fluctuating high (13.0%). The primary endpoint occurred in 15.02%, 25.20%, and 36.08% of patients, respectively (p < 0.001). In adjusted models, the fluctuating high group showed increased risk for the composite endpoint (HR 1.91, 95% CI 1.25-2.91) and heart failure hospitalization (HR 1.91, 95% CI 1.19-3.06), while the decreasing group showed an association with myocardial infarction based on few events (HR 3.00, 95% CI 1.33-6.76). Adding trajectory information produced a modest improvement in risk prediction (C-index 0.758 to 0.765; AUC 0.786 to 0.792 at 4 years and 0.832 to 0.845 at 6 years, p = 0.0149). This study first identified distinct uACR trajectory patterns in HFpEF patients. The fluctuating high trajectory was associated with increased cardiovascular risk and heart failure hospitalization, while the association between the decreasing trajectory and myocardial infarction was exploratory and requires validation.
Topics
Primary Source
Clinical cardiology
Ask Prognia AI
Have questions about this randomised trial?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.